

ASX ANNOUNCEMENT

11 January 2024



Reset Mind Sciences sponsored WA Psilocybin Clinical Trial Opens

- Western Australian Clinical Trial into efficacy and safety of psilocybin assisted therapy involving family members for patients with treatment resistant major depressive disorder launched and first Trial patient scheduled for clinical visit
- Screening of potential Trial participants has commenced with Trial expected to take approximately 12 months to complete
- Focused on development and refinement of best practice psychotherapy protocols to accompany administration of psilocybin
- Sponsored by Reset Mind Sciences with leading academic and consultant psychiatrist Professor Sean Hood (University of Western Australia) as Principal Investigator
- Will be conducted at Harry Perkins Institute of Medical Research in Perth, Western Australia in conjunction with Fiona Stanley Hospital
- Is expected to be the first clinical trial to be conducted in Western Australia using psilocybin
- Takes on heightened relevance and significance following the TGA's decision to down-schedule psilocybin in defined circumstances for use with treatment resistant depression
- Demerger of Reset Mind Sciences advancing, with Capital Raising Prospectus Offer open with Closing Date of 5pm AWST, 16 January 2024





Little Green Pharma Ltd.'s (ASX: LGP, “LGP” or the “Company”) psychedelics focused subsidiary Reset Mind Sciences Ltd (**Reset**) is pleased to announce the launch of its clinical Trial (**Clinical Trial** or **Trial**) into the efficacy and safety of psilocybin assisted therapy involving family members for patients with treatment resistant major depressive disorder.

The clinical Trial, anticipated to take 12 months to complete, builds on the increasing body of research globally into the use of psilocybin to treat depressive related conditions by incorporating key family members into the preparatory and integration therapy sessions that precede and follow the psilocybin administration sessions.

Screening of potential Trial participants has commenced with the first clinical visit by a Trial participant scheduled.

The Trial will include 60 participants and will be conducted at the Harry Perkins Institute of Medical Research in Perth, Western Australia in conjunction with Fiona Stanley Hospital. It is expected to be the first clinical trial to be conducted in Western Australia using psilocybin.

Last year, Reset received Human Research Ethics Committee (HREC) approval¹ for the Trial which took on added significance and relevance following the Therapeutic Goods Administration's (TGA) announcement in February 2023 that it had changed the classification of psilocybin within certain defined parameters for the treatment of Treatment Resistant Depression from 1 July 2023.²



Reset Mind Sciences Chief Operating Officer Dr Leon Warne said:

“The official launch of our clinical Trial is a key milestone in the short history of Reset Mind Sciences.

We anticipate this Trial, which will be one of the first psilocybin assisted therapy trials in Australia, will contribute meaningfully to the clinical evidence supporting the use of psilocybin for the treatment of chronic mental illness in Australia.

Our focus now is on screening and recruitment of potential participants to undertake the clinical Trial; with our first participant scheduled for their first visit to the Harry Perkins Institute of Medical Research later this month.”

The clinical therapy team conducting the Trial is led by one of Australia's most respected psychiatrists Prof. Sean Hood as Principal Investigator and Reset Advisory Board members Dr. Stephen Bright and Ms Renee Harvey.

¹Refer to ASX announcement dated 15th February 2023

²Refer to ASX announcement dated 6th February 2023



Reset Demerger

On 9 November 2023, LGP announced it was seeking LGP shareholder approval to demerge Reset Mind Sciences Limited (Reset or the Company) from the LGP Group.

LGP has proposed to demerge Reset through a pro-rata in-specie distribution of its 10,000,000 shares in Reset to eligible LGP shareholders (In-Specie Distribution), on the basis of one share in Reset for approximately every 30 LGP shares held by eligible LGP shareholders as at 5:00pm (AWST) on 23 January 2024 (In-specie Record Date).

The shareholders' meeting to consider the demerger and associated In-Specie Distribution will be held on 4:00pm (AWST) on Wednesday, 17 January 2024, with the demerger being conditional upon successful completion of the capital raise discussed below.

Reset Capital Raising Prospectus Offer closing on 5pm AWST on Tuesday, 16th January 2024

Reset proposes to undertake a capital raise to raise up to \$2 million (before costs) by the issue of up to 10,000,000 ordinary shares in Reset (**Reset Shares**) at \$0.20 per share (**Offers**).

On 9 November 2023, Reset lodged a Prospectus with the Australian Securities and Investments Commission containing three offers (**Offers**), comprising:

- a pro-rata priority offer to eligible LGP shareholders of up to 5,000,000 Reset Shares at a price of \$0.20 per share, to raise up to \$1,000,000 (before costs) (**Priority Offer**)
- a chair's list offer of up to 2,500,000 Reset Shares at a price of \$0.20 per share, to raise up to \$500,000 (before costs) (**Chair's List Offer**)
- a public offer of up to 2,500,000 Reset Shares at a price of \$0.20 per share, to raise up to \$500,000 (before costs) (**Public Offer**)

The Company has also reserved the right to accept oversubscriptions under the Public Offer of up to an additional \$1,000,000 for a total potential raising amount of \$3,000,000 (before costs).

As advised on 4 January 2024, the Prospectus Offers, comprising the Priority Offer, Public Offer and Chair's List Offer, were extended and will now close on 5pm AWST on Tuesday, 16th January 2024 to give certain UK international investors the opportunity to obtain regulatory approval for their proposed investment under the Prospectus Offers and to make a final investment decision.

In respect of applications under the Priority Offer, the Company reminds eligible LGP shareholders, that in order to access a replacement application letter which includes their unique priority access code, shareholders can download their application letter via Automic's single holding access page at <https://investor.automic.com.au/#/loginsah> using their LGP HIN/SRN and postcode.

Further information on the Offers including a copy of the Offer Prospectus is available here: <https://www.resetmind.com.au/demerger>

Extraordinary General Meeting

The Extraordinary General Meeting seeking shareholder approval for the demerger of Shares in Reset to eligible LGP shareholders will take place on 17 January 2024.

Please refer to ASX announcement dated 4th January 2024 for instructions on how to attend the EGM. Further information on how to vote and attend the Extraordinary General Meeting is available here: <https://www.investlittlegreenpharma.com/site/investor-centre/reset-demerger-prospectus>

ENDS
BY ORDER OF THE BOARD



Alistair Warren
Company Secretary



For further information please contact:

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

Dr Leon Warne
Chief Operating Officer
Reset Mind Sciences
E: Leon.Warne@resetmind.com.au
T: +61 8 6280 0050

Media: David Tasker
Managing Director
Chapter One Advisors
E: dtasker@chapteroneadvisors.com.au
T: +61 433 112 936 / +61 439 980 359

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomass per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp